The GIP activation may provide some protective effect against GLP-1-related nausea, a pattern also observed with Tirzepatide
For chronic weight management, the FDA-approved indications generally include adults with a BMI of 30 or greater, or BMI 27 or greater with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
May Reduce Autoimmune Antibodies (Emerging Data) Some early evidence suggests GLP-1s may have immune-modulating effects
CRUSHS is a protein ice cream mix also made for the Ninja Creami
Sometimes coverage is available for other FDA-approved uses, such as Zepbound for obstructive sleep apnea or Wegovy for cardiovascular protection
Please consult a medical professional before adopting any of the suggestions on this page